GlassScriptPhysician profile
Douglas G Hoff
NPI 1801815519
$635.38
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $26.48 · 2021: $27.75 · 2022: $21.56 · 2023: $60.60 · 2024: $47.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $108.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $293.70 | 2019-2020 | |
| Amgen INC. | $105.63 | 2019 | |
| Boston Scientific Corporation | $60.60 | 2023 | |
| Sumitomo Pharma America, INC. | $28.53 | 2024 | Orgovyx |
| Endo Pharmaceuticals INC. | $25.71 | 2019 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Merck Sharp & Dohme LLC | $21.56 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.98 | 2024 | |
| Astellas Pharma US INC | $18.19 | 2019 | |
| Pfizer INC. | $13.17 | 2019 | |
| Travere Therapeutics, INC. | $3.82 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,127.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Hoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.